Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defibrinogenating enzymes

W R Bell1

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Drugs
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Snake venom fractions ancrod, batroxobin, and crotalase reduce fibrinogen levels by cleaving fibrinogen. These defibrinogenating agents show potential in treating thrombotic conditions and have laboratory applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oxidative damage in age-related macular degeneration.

Histology and histopathology·2007
Same author

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells.

British journal of cancer·2004
Same author

Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow.

The pharmacogenomics journal·2003
Same author

Role of splenectomy in immune (idiopathic) thrombocytopenic purpura.

Blood reviews·2002
Same author

Thrombotic thrombocytopenic purpura associated with clopidogrel.

The New England journal of medicine·2000
Same author

Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia.

Blood·2000
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Snake venoms contain enzymes that affect blood coagulation.
  • Ancrod, batroxobin, and crotalase are snake venom fractions known to induce defibrinogenation.
  • Their primary action involves proteolytic cleavage of circulating fibrinogen.

Purpose of the Study:

  • To investigate the properties and effects of ancrod, batroxobin, and crotalase.
  • To explore their potential therapeutic applications in thrombotic disorders.
  • To assess their utility as laboratory reagents in coagulation testing.

Main Methods:

  • Purification of ancrod, batroxobin, and crotalase from snake venoms.
  • Characterization of their enzymatic properties (coagulant, proteolytic, esterolytic).

Related Experiment Videos

  • Administration studies in animal models and limited human trials for ancrod and batroxobin.

    • Main Results:

    • Ancrod, batroxobin, and crotalase effectively reduce plasma fibrinogen levels.
    • Ancrod cleaves only A-fibrinopeptides, while batroxobin and crotalase cleave both A and B fibrinopeptides.
    • Treatment leads to decreased blood viscosity and increased fibrinogen-fibrin degradation products.
    • Ancrod and batroxobin have been explored for thrombotic conditions with mixed results.
    • These agents are useful in laboratory assays for heparinized blood samples.

    Conclusions:

    • Ancrod, batroxobin, and crotalase are potent defibrinogenating agents with distinct cleavage specificities.
    • Therapeutic efficacy in thrombotic diseases requires further well-designed clinical trials.
    • These snake venom fractions serve as valuable tools in diagnostic coagulation testing.